Details of Protein
General Information of Protein (ID: PRT01692) | |||||
---|---|---|---|---|---|
Name | Glucagon receptor (GCGR) | ||||
Synonyms |
Click to Show/Hide Synonyms of This Protein
GL-R
|
||||
Gene Name | Gcgr | Gene ID | |||
UniProt ID | |||||
Family | GPCR secretin (GPCR-2) | ||||
Click to Show/Hide the Molecular/Functional Data (Sequence/Structure/Function) of This Protein | |||||
Sequence |
MPLTQLHCPHLLLLLLVLSCLPEAPSAQVMDFLFEKWKLYSDQCHHNLSLLPPPTELVCN
RTFDKYSCWPDTPPNTTANISCPWYLPWYHKVQHRLVFKRCGPDGQWVRGPRGQPWRNAS QCQLDDEEIEVQKGVAKMYSSQQVMYTVGYSLSLGALLLALVILLGLRKLHCTRNYIHGN LFASFVLKAGSVLVIDWLLKTRYSQKIGDDLSVSVWLSDGAMAGCRVATVIMQYGIIANY CWLLVEGVYLYSLLSLATFSERSFFSLYLGIGWGAPLLFVIPWVVVKCLFENVQCWTSND NMGFWWILRIPVFLALLINFFIFVHIIHLLVAKLRAHQMHYADYKFRLARSTLTLIPLLG VHEVVFAFVTDEHAQGTLRSTKLFFDLFLSSFQGLLVAVLYCFLNKEVQAELMRRWRQWQ EGKALQEERLASSHGSHMAPAGPCHGDPCEKLQLMSAGSSSGTGCVPSMETSLASSLPRL ADSPT |
||||
Function | G-protein coupled receptor for glucagon that plays a central role in the regulation of blood glucose levels and glucose homeostasis. Regulates the rate of hepatic glucose production by promoting glycogen hydrolysis and gluconeogenesis. Plays an important role in mediating the responses to fasting. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Promotes activation of adenylate cyclase. Besides, plays a role in signaling via a phosphatidylinositol-calcium second messenger system. | ||||
Regulatory Network | |||||
Full List of Metabolite(s) Regulated by This Protein | ||||||
---|---|---|---|---|---|---|
Nucleosides, nucleotides, and analogues | ||||||
Cyclic AMP | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[1] | ||||
Introduced Variation | Antagonist (GRA1) of Gcgr | |||||
Induced Change | Cyclic AMP concentration: decrease | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Hyperglycemic hyperosmolar syndrome [ICD-11: 5A20] | |||||
Details | It is reported that antagonist of GCGR leads to the decrease of cyclic AMP levels compared with control group. | |||||
dCMP | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | dCMP concentration: increase (FC = 2.8) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the increase of dCMP levels compared with control group. | |||||
dUTP | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | dUTP concentration: decrease (FC = 1.3) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the decrease of dUTP levels compared with control group. | |||||
S-Adenosylhomocysteine | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | S-Adenosylhomocysteine concentration: decrease (FC = 3.4) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the decrease of s-adenosylhomocysteine levels compared with control group. | |||||
UDP glucose | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | UDP glucose concentration: decrease (FC = 1.9) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the decrease of UDP glucose levels compared with control group. | |||||
Uridine | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | Uridine concentration: increase (FC = 1.7) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the increase of uridine levels compared with control group. | |||||
Uridine 5'-monophosphate | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | Uridine 5'-monophosphate concentration: increase (FC = 2.1) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the increase of uridine 5'-monophosphate levels compared with control group. | |||||
Lipids and lipid-like molecules | ||||||
Cholic acid | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | Cholic acid concentration: increase (FC = 244.30) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the increase of cholic acid levels compared with control group. | |||||
Glycocholic acid | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | Glycocholic acid concentration: increase (FC = 154) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the increase of glycocholic acid levels compared with control group. | |||||
Organic acids and derivatives | ||||||
4-Hydroxyproline | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | 4-Hydroxyproline concentration: increase (FC = 2.7) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the increase of 4-hydroxyproline levels compared with control group. | |||||
Alanine | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | Alanine concentration: increase (FC = 5.1) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the increase of alanine levels compared with control group. | |||||
Aminoadipic acid | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | Aminoadipic acid concentration: increase (FC = 5.4) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the increase of aminoadipic acid levels compared with control group. | |||||
Arginine | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | Arginine concentration: increase (FC = 3.9) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the increase of arginine levels compared with control group. | |||||
Argininosuccinic acid | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | Argininosuccinic acid concentration: increase (FC = 3.7) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the increase of argininosuccinic acid levels compared with control group. | |||||
Asparagine | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | Asparagine concentration: increase (FC = 8.1) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the increase of asparagine levels compared with control group. | |||||
Aspartic acid | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | Aspartic acid concentration: increase (FC = 3.6) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the increase of aspartic acid levels compared with control group. | |||||
Betaine | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | Betaine concentration: increase (FC = 2.8) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the increase of betaine levels compared with control group. | |||||
Citrulline | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | Citrulline concentration: increase (FC = 3.3) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the increase of citrulline levels compared with control group. | |||||
Creatine | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | Creatine concentration: increase (FC = 2) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the increase of creatine levels compared with control group. | |||||
Cysteine | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | Cysteine concentration: increase (FC = 2.7) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the increase of cysteine levels compared with control group. | |||||
D-Ornithine | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | D-Ornithine concentration: increase (FC = 5.4) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the increase of D-Ornithine levels compared with control group. | |||||
Dihydrofolic acid | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | Dihydrofolic acid concentration: increase (FC = 5.3) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the increase of dihydrofolic acid levels compared with control group. | |||||
Dimethylglycine | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | Dimethylglycine concentration: increase (FC = 3.1) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the increase of dimethylglycine levels compared with control group. | |||||
Gamma-Aminobutyric acid | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | Gamma-Aminobutyric acid concentration: increase (FC = 1.5) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the increase of gamma-aminobutyric acid levels compared with control group. | |||||
Glutamic acid | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | Glutamic acid concentration: increase (FC = 2.4) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the increase of glutamic acid levels compared with control group. | |||||
Glutamine | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | Glutamine concentration: increase (FC = 2.9) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the increase of glutamine levels compared with control group. | |||||
Glycine | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | Glycine concentration: increase (FC = 7.8) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the increase of glycine levels compared with control group. | |||||
Histidine | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | Histidine concentration: increase (FC = 4) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the increase of histidine levels compared with control group. | |||||
Homocysteine | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | Homocysteine concentration: increase (FC = 2.4) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the increase of homocysteine levels compared with control group. | |||||
L-Cystathionine | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | L-Cystathionine concentration: increase (FC = 3.7) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the increase of L-cystathionine levels compared with control group. | |||||
L-Homoserine | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | L-Homoserine concentration: increase (FC = 3) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the increase of L-homoserine levels compared with control group. | |||||
L-Targinine | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | L-Targinine concentration: increase (FC = 4.3) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the increase of L-targinine levels compared with control group. | |||||
Lysine | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | Lysine concentration: increase (FC = 2.9) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the increase of lysine levels compared with control group. | |||||
Methionine | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | Methionine concentration: increase (FC = 1.6) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the increase of methionine levels compared with control group. | |||||
Oxidized glutathione | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | Oxidized glutathione concentration: decrease (FC = 2.1) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the decrease of oxidized glutathione levels compared with control group. | |||||
Oxoglutaric acid | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | Oxoglutaric acid concentration: increase (FC = 2.3) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the increase of oxoglutaric acid levels compared with control group. | |||||
Phospho-tyrosine | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | Phospho-tyrosine concentration: decrease | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the decrease of phospho-tyrosine levels compared with control group. | |||||
Phosphoenolpyruvate | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | Phosphoenolpyruvate concentration: decrease (FC = 2.3) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the decrease of phosphoenolpyruvate levels compared with control group. | |||||
Proline | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | Proline concentration: increase (FC = 2.3) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the increase of proline levels compared with control group. | |||||
Serine | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | Serine concentration: increase (FC = 8.7) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the increase of serine levels compared with control group. | |||||
Symmetric dimethylarginine | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | Symmetric dimethylarginine concentration: increase (FC = 1.7) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the increase of symmetric dimethylarginine levels compared with control group. | |||||
Threonine | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | Threonine concentration: increase (FC = 9.6) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the increase of threonine levels compared with control group. | |||||
Tyrosine | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | Tyrosine concentration: increase (FC = 1.7) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the increase of tyrosine levels compared with control group. | |||||
Ureidopropionic acid | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | Ureidopropionic acid concentration: increase (FC = 1.7) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the increase of ureidopropionic acid levels compared with control group. | |||||
Valine | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | Valine concentration: increase (FC = 1.3) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the increase of valine levels compared with control group. | |||||
Organic nitrogen compounds | ||||||
Choline | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | Choline concentration: decrease (FC = 1.3) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the decrease of choline levels compared with control group. | |||||
Trimethylamine N-oxide | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | Trimethylamine N-oxide concentration: increase (FC = 1.7) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the increase of trimethylamine N-oxide levels compared with control group. | |||||
Organic oxygen compounds | ||||||
3-Phosphoglyceric acid | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | 3-Phosphoglyceric acid concentration: decrease (FC = 2.2) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the decrease of 3-phosphoglyceric acid levels compared with control group. | |||||
Alpha-Lactose | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | Alpha-Lactose concentration: decrease (FC = 2) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the decrease of alpha-Lactose levels compared with control group. | |||||
Fructose | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | Fructose concentration: decrease (FC = 1.4) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the decrease of fructose levels compared with control group. | |||||
Glucose | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | Glucose concentration: decrease (FC = 1.4) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the decrease of glucose levels compared with control group. | |||||
Glyceraldehyde | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | Glyceraldehyde concentration: decrease (FC = 1.3) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the decrease of glyceraldehyde levels compared with control group. | |||||
Glycerol | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | Glycerol concentration: decrease (FC = 2.7) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the decrease of glycerol levels compared with control group. | |||||
Pantothenic acid | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | Pantothenic acid concentration: increase (FC = 1.7) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the increase of pantothenic acid levels compared with control group. | |||||
Organoheterocyclic compounds | ||||||
4-Pyridoxic acid | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | 4-Pyridoxic acid concentration: increase (FC = 2) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the increase of 4-pyridoxic acid levels compared with control group. | |||||
5-Hydroxy-L-tryptophan | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | 5-Hydroxy-L-tryptophan concentration: increase (FC = 2.2) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the increase of 5-hydroxy-L-tryptophan levels compared with control group. | |||||
5-Methyltetrahydrofolic acid | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | 5-Methyltetrahydrofolic acid concentration: increase (FC = 3.6) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the increase of 5-methyltetrahydrofolic acid levels compared with control group. | |||||
Ascorbic acid | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | Ascorbic acid concentration: decrease (FC = 1.2) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the decrease of ascorbic acid levels compared with control group. | |||||
Biotin | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | Biotin concentration: increase (FC = 1.6) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the increase of biotin levels compared with control group. | |||||
Guanine | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | Guanine concentration: increase (FC = 2.3) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the increase of guanine levels compared with control group. | |||||
Kynurenic acid | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | Kynurenic acid concentration: decrease (FC = 2.3) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the decrease of kynurenic acid levels compared with control group. | |||||
Orotic acid | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | Orotic acid concentration: increase (FC = 1.6) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the increase of orotic acid levels compared with control group. | |||||
Pyridoxal 5'-phosphate | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | Pyridoxal 5'-phosphate concentration: increase (FC = 1.5) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the increase of pyridoxal 5'-phosphate levels compared with control group. | |||||
Pyridoxine | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Metabo Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Knockout of Gcgr | |||||
Induced Change | Pyridoxine concentration: increase (FC = 3.6) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Details | It is reported that knockout of GCGR leads to the increase of pyridoxine levels compared with control group. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.